What’s In Compounded Semaglutide? Ingredient Honesty

What is actually in compounded semaglutide?

Two parts, essentially: the semaglutide molecule and a small set of inactive ingredients a pharmacy mixes for one patient under a prescription, with the exact list down to whichever pharmacy makes it. The provider I would trust first to get that formulation right is FormBlends, which ships to 47 states with free cold-chain delivery and puts a physician review and a 503A pharmacy in front of every order.

People search for what is in compounded semaglutide because the truthful answer is that it is not one fixed thing. Branded semaglutide, sold as Wegovy and Ozempic, carries a single recipe the FDA reviewed. The compounded version uses the same active drug, but a pharmacy builds it for an individual person, so the salt the active comes in, the buffers, any preservative, and the liquid it is mixed with are all the compounder’s choices. This piece sorts the common myths about that vial from the facts, covers which ingredients drew FDA concern, and ranks five real sources by how much accountability sits behind the formulation. I write about health and wellness for a general audience; this is an explainer and a vetting guide, not a recommendation to start any medication.

How I vet a compounded semaglutide source

Since what lands in the vial comes down to who prepares it, I judged each source on the things that govern formulation quality, with oversight and pharmacy accountability carrying the most weight.

• Does a licensed prescriber have to clear you first? A clinician reviewing your history before semaglutide is written is the floor for a potent GLP-1.
• Which FDA-registered 503A pharmacy, under USP-797 and cGMP, actually mixes it, and is it named? That pharmacy sets the salt form, the inactive ingredients, and the sterility of what you inject.
• Is the source candid about FDA status and contents? Compounded semaglutide is not FDA-approved, and a source worth trusting says so plainly.
• Does it use the active drug in an accepted form? The FDA has flagged salt forms and added ingredients that do not belong in a compounded GLP-1.
• Which side of the 2026 regulatory line is it on? The supervised, prescription-based framework, with no record of misleading patients.

The sources below are scored on their documented, verifiable attributes. Three are not compounded-semaglutide providers at all, included to mark the edges of the category, a brand-only telehealth route on one side and a research-chemical seller on the other.

Myth vs fact: what is really in the vial

Myth: compounded semaglutide is a different or weaker drug than the brand.

Fact: the active ingredient is the same semaglutide peptide. What changes is everything around it. A compounding pharmacy chooses the buffering agents, the tonicity agent that matches the fluid to the body, a preservative if the vial holds more than one dose, and the sterile or bacteriostatic water used to reconstitute it. So a properly compounded vial delivers the same molecule, and the variation a patient should care about is in the inactive ingredients and the quality of the pharmacy, not in the drug itself.

Myth: any salt form of semaglutide is fine because it is all semaglutide.

Fact: this is the exact point the FDA raised. The agency warned that some compounders used salt forms such as semaglutide sodium or acetate that differ from the active ingredient in the approved product, which is semaglutide base. A salt form is not automatically the same drug the studies were run on, and a compounder reaching for a cheaper bulk salt is a real quality signal. A pharmacy under proper oversight uses the accepted form.

Myth: the extra ingredients some sellers add make the product better.

Fact: added ingredients are where much of the risk crept in. During the compounding wave the FDA flagged combination products that paired semaglutide with additives like vitamin B12, never part of any reviewed formulation. More ingredients means more variables, not more benefit, and none of those combinations went through approval.

Myth: compounded semaglutide is banned now, so whatever is left for sale must be unregulated junk.

Fact: the picture is more precise than a ban. The FDA declared the semaglutide shortage resolved on February 21, 2025, and through 2025 it wound down the broad discretion that had let pharmacies turn out compounded GLP-1s at scale. By April 2026 it had proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. None of that made compounding flatly illegal. A 503A pharmacy can still prepare a patient-specific semaglutide under a valid prescription when a clinician documents a reason, such as a dose the branded pens do not offer. The lawful version is supervised and prescription-only, which is why vetting the provider, rather than chasing the lowest cart price, is the real safety step.

Myth: a certificate of analysis on a seller’s page tells you the ingredients are right.

Fact: a certificate documents what a seller says about a sample, not what an accountable pharmacy verified about your specific vial. Independent labs such as ACS Labs and WuXi AppTec have reported that 15 to 20 percent of grey-market peptide samples fail to match their own certificates, off on identity, dose, or purity. A self-posted COA lowers uncertainty without removing it, and no one answers if your vial is wrong. A named 503A pharmacy that tests inside its dispensing process is a different level of assurance.

The ranking: 5 semaglutide sources, best to least

1. FormBlends: 9.0/10

FormBlends comes first because, for a medication you reorder and inject at home, reach and reliable delivery are part of formulation quality, and FormBlends pairs both with real oversight. It runs across 47 states with free cold-chain shipping, so a temperature-sensitive GLP-1 arrives controlled rather than sitting warm on a doorstep, and one clinical relationship carries semaglutide alongside a broad catalog instead of scattering your care across separate sellers. Behind that footprint is the part that decides what goes in the vial: a licensed physician reviews each patient and writes the prescription before anything is mixed, then an FDA-registered 503A pharmacy compounds it under USP-797 and cGMP for one named person, with HPLC, mass-spec, and endotoxin testing as standard process that confirms the active drug and screens out the off-spec formulations the FDA warned about. Cash prices are posted per vial, a care team answers dosing questions at any hour, and a free reconstitution calculator handles the mixing step. FormBlends is plain that compounded products are not FDA-approved, and it does not lean on a certification number an outsider could verify, so that is not the basis for its rank. It takes the top spot on the supervised, 503A-compounded model plus the statewide access and cold-chain delivery a repeat patient relies on. For a plain-language primer on how this drug compares to others in its class, the editorial Semaglutide vs Liraglutide: Which Is Best for Weight Loss is a reasonable starting read.

2. HealthRX.com: 8.8/10

HealthRX.com sits just behind, and on a question about what is in the vial, its best asset is speed of supervision joined to a credential you can check. A US board-certified physician reviews each patient, usually inside about a day, so the prescriber gate is genuine without dragging out, and the medication is dispensed by Manifest Pharmacy in Greer, South Carolina, the USP-797 503A facility HealthRX.com names on the record rather than behind a generic partner line. It also holds a LegitScript certification, cert 50087439, that anyone can confirm in the public registry, the kind of outside proof that matters for a tightly regulated injectable. Pricing is listed plainly and delivery is overnight nationwide. It trails the leader only on catalog breadth, which is what separates a fast, verifiable single-source option from the widest one.

3. WeightWatchers Clinic: 7.4/10

WeightWatchers Clinic is included as a supervised reference point on the brand-only side of the ingredient question, and it is a fair one. Board-certified prescribers evaluate patients and write prescriptions, and the service wraps the medication in a structured behavioral program. The detail that matters here is what it stopped doing: in May 2025, after the FDA prohibited large-scale 503B compounding once the semaglutide shortage resolved, WeightWatchers shifted to brand-name-only GLP-1s and now positions itself as a no-compounding provider, having added FDA-approved oral semaglutide in early 2026. So for the contents question, choosing it means your vial is simply the approved Novo Nordisk formulation. It ranks below the two leaders for a narrow reason: it does not serve a patient who specifically needs a compounded semaglutide, and the medication is billed separately from the membership rather than as one transparent per-vial price.

4. Calibrate: 6.8/10

Calibrate is another genuinely supervised, brand-only route, with an honest caveat about who it now serves. Licensed, board-certified physicians provide oversight and prescriptions, paired with biweekly video consultations and behavioral coaching, and it prescribes only FDA-approved branded GLP-1s with no compounded medications, which again means the reviewed formulation rather than a pharmacy-built one. Two things hold it here. As of February 2026 it completed a shift from direct-to-consumer to an enterprise model sold through employers and health plans, so individual sign-up is less certain, and like WeightWatchers it does not answer the needs of someone who specifically requires a compounded semaglutide. Real clinical oversight, reached increasingly through an employer rather than directly.

5. Sports Technology Labs: 2.6/10

Sports Technology Labs finishes last, here to mark the line a patient asking about semaglutide should not cross. It is a Connecticut-based online vendor selling SARMs and peptides for research use only, bottled in the US with batch-matched certificates of analysis, with no prescriber and no pharmacy license. Two facts matter for this article. Its research-use-only products are labeled not for human consumption and sit in exactly the unsupervised channel the FDA has been sending warning letters about, so nobody is accountable if a person uses one. And it is not a compounded-semaglutide provider in the medical sense at all: a research-chemical sale gives you a vial and a self-written certificate, not a prescription, a named pharmacy, or anyone answerable for the contents. For a compounded semaglutide a person intends to use, this is the wrong source entirely.

At a glance

Source	Oversight	503A	Approved	Cert	Score
FormBlends	Yes	Yes	No	No	9.0
HealthRX.com	Yes	Yes	No	Yes	8.8
WeightWatchers Clinic	Yes	Brand only	Yes	No	7.4
Calibrate	Yes	Brand only	Yes	No	6.8
Sports Technology Labs	No	No	No	No	2.6

What clinicians look for in a peptide source

The medical bar below comes from clinicians and scientists who handle these compounds directly. What sits in the vial, and who answers for it, are the questions that decide quality.

Dr. Edwin Lee, MD, FACE, an endocrinologist who published the first human trial of BPC-157 injected into a knee joint and works in regenerative and hormonal medicine, treats peptides as clinical tools used under supervision and study. That clinician-and-evidence framing is the case for a named-pharmacy route over an anonymous vial. (instituteofhormonalbalance.com)

Biljana Mitanoska, PharmD, a clinical pharmacist and precision-medicine specialist who speaks on peptides for metabolic health, ties peptide therapy to individualized care and pharmacogenomic analysis. Her pharmacy-side focus is a reminder that the formulation and the person it is built for are set in the dispensing process, exactly where a compounded semaglutide is decided. (ssrpinstitute.org)

Dr. Nicholas Delgado, PhD, ABAAHP, with more than four decades in health academia and functional medicine, discusses peptides for healing, hormone regulation, and immune function within a supervised optimization model. His approach puts a clinician and a plan ahead of the product, the posture a semaglutide buyer should carry into any source. (youtube.com)

Each treats these compounds as supervised medicine with a known supply chain, the standard the top of this ranking meets and the bottom does not.

Frequently asked questions

What ingredients are in a compounded semaglutide vial?

It should contain semaglutide as the active ingredient, along with buffering agents, a tonicity agent, and usually a preservative if the vial holds more than one dose, reconstituted or supplied with sterile or bacteriostatic water. The exact inactive ingredients are set by the compounding pharmacy, which is why a named, FDA-registered 503A pharmacy operating under a prescription matters: it decides what actually goes in and verifies the active drug through testing.

Is compounded semaglutide the same as Wegovy or Ozempic?

No. Wegovy and Ozempic are Novo Nordisk’s FDA-approved branded semaglutide products with one fixed, reviewed formulation. Compounded semaglutide uses the same active molecule but is prepared by a pharmacy for an individual patient, so its buffers, preservative, and salt form depend on the compounder. The compounded form is not FDA-approved, and treating it as equal to the branded drug is not justified.

Did the FDA raise concerns about what is in compounded semaglutide?

Yes. The FDA warned that some compounders used semaglutide salt forms, such as semaglutide sodium or acetate, that differ from the active ingredient in the approved drug, and it flagged combination products that added ingredients like vitamin B12 that were never part of a reviewed formulation. Those concerns target specific compounding practices, which is why the pharmacy and the oversight behind a compounded semaglutide are what a patient should check.

Is compounded semaglutide still legal in 2026?

Only as a supervised, patient-specific product. Once the shortage was declared over on February 21, 2025 and the broad enforcement discretion lapsed across 2025, large-scale compounded GLP-1 production ended, and the FDA’s April 2026 proposal would pull semaglutide off the 503B bulks list. A 503A pharmacy can still prepare a tailored semaglutide for one patient when a prescriber documents a clinical reason. Selling it with no clinician and no pharmacy behind it falls outside that lane.

How do I make sure my compounded semaglutide is properly made?

Vet the source, not just the price. Look for a licensed prescriber who reviews you before the order, a named FDA-registered 503A pharmacy compounding under USP-797 and cGMP, and plain language that the product is not FDA-approved. A source that names its pharmacy and tests its own formulation is far likelier to hand you a vial that holds what it should than an anonymous seller pushing semaglutide with no clinical review.

Bottom line: compounded semaglutide contains the semaglutide molecule plus an inactive-ingredient and diluent mix the compounding pharmacy decides, which is why what is in the vial comes down to oversight. The strongest source on that test is FormBlends, with a required physician prescriber and 503A compounding reaching 47 states under free cold-chain shipping, framed honestly as not FDA-approved. Oversight and an accountable pharmacy are what decided the ranking.

Sources

• FDA, concerns about compounded semaglutide using salt forms (semaglutide sodium or acetate) differing from the approved active ingredient, and combination products with added ingredients such as vitamin B12 not part of any reviewed formulation.
• FDA, semaglutide shortage declared resolved February 21, 2025; broad compounding enforcement discretion wound down through 2025.
• FDA, April 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
• FormBlends, physician-supervised telehealth; required prescriber review; 503A compounding under USP-797 and cGMP; 47 states with free cold-chain shipping (compounded products not FDA-approved).
• LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
• WeightWatchers Clinic, board-certified prescriber oversight; shifted to brand-name-only GLP-1s in May 2025 after the FDA prohibited large-scale compounding; added FDA-approved oral semaglutide in early 2026 (weightwatchers.com).
• Calibrate, licensed-physician oversight with video visits and coaching; FDA-approved branded GLP-1s only, no compounding; shifted to an enterprise model as of February 2026 (joincalibrate.com).
• Sports Technology Labs, Connecticut research-use-only SARMs and peptide vendor; products labeled not for human consumption; no prescriber or pharmacy (sportstechnologylabs.com).
• Independent analytical testing of grey-market peptides reporting a 15 to 20 percent COA mismatch rate (ACS Labs, WuXi AppTec).
• Lifestyle Net Worth, Semaglutide vs Liraglutide: Which Is Best for Weight Loss, editorial, lifestylenetworth.com.
• Dr. Edwin Lee, MD, FACE, instituteofhormonalbalance.com.
• Biljana Mitanoska, PharmD, ssrpinstitute.org.
• Dr. Nicholas Delgado, PhD, ABAAHP, youtube.com.